Is Foundayo the Same as Tirzepatide? How the Two Medicines Actually Compare

• A direct answer: is Foundayo tirzepatide, and why the two names get confused
• How the two medicines actually differ, from receptor targets to how they are taken
• What happened when trial participants switched from tirzepatide to Foundayo
• Online consultation with UK-registered prescribers to find out which approach may suit you

No, Foundayo is not tirzepatide. Foundayo is the brand name for orforglipron, a non-peptide GLP-1 receptor agonist taken as a daily tablet, while tirzepatide is sold in the UK as Mounjaro and is a peptide dual GLP-1 and GIP receptor agonist given by weekly injection. They are two different active ingredients, built differently, used differently, and studied differently. The confusion is understandable: both come from Eli Lilly, both are relevant to weight management, and a trial has directly connected the two. Whichever way you put it, whether you are asking is Foundayo a tirzepatide medicine, or Foundayo is it tirzepatide, the answer is the same.

For adults in the UK looking at weight management treatment options through licensed and private prescribing services, the key question is not just whether the names are linked, but how these medicines differ in practice. This guide answers that by comparing how Foundayo and tirzepatide work, how they are taken, how their results and side effects compare, what their licensing position means for weight management and type 2 diabetes, what the switching trial from tirzepatide to Foundayo showed, and what may shape the choice between them. Our Foundayo medicine guide covers what orforglipron is in its own right, and our Foundayo research guide covers the wider trial programme; this guide focuses specifically on the comparison with tirzepatide.

Key things to know

• Foundayo (orforglipron) and tirzepatide (Mounjaro) are different medicines with different active ingredients
• Tirzepatide activates two receptors, GLP-1 and GIP. Foundayo activates GLP-1 only
• Tirzepatide is a peptide given by weekly injection. Foundayo is a non-peptide small molecule taken as a daily tablet
• In separate 72-week trials, the highest studied tirzepatide dose produced roughly twice the average weight loss seen with the highest studied Foundayo dose, although the medicines were not compared directly in the same trial.
• A dedicated switching trial found people who had plateaued on tirzepatide kept most of their weight loss after moving to Foundayo, far more than those switched to placebo.
• Both medicines are licensed in the UK for weight management and for type 2 diabetes.

Is Foundayo Tirzepatide? The Direct Answer

Foundayo and tirzepatide are not the same medicine, not the same molecule, and not interchangeable. Foundayo's active ingredient is orforglipron. Tirzepatide is sold in the UK as Mounjaro. Both belong to the same broad medicine class, GLP-1 receptor agonists, which is likely the reason searches conflate them, but belonging to the same class is not the same as being the same medicine, any more than two different antibiotics are the same medicine because both are antibiotics.

Four things explain why the names end up next to each other in searches: both are made by Eli Lilly, both are prescribed for weight management in the UK, both appear in the same online discussions about newer weight-management options, and a clinical trial has directly studied moving from one to the other, covered below. None of that makes them the same medicine.

Foundayo vs Tirzepatide: GLP 1 Mechanism

The clearest difference is which receptors each medicine acts on.

The receptor difference is the more significant of the two for how each medicine behaves in the body. Tirzepatide's action at the GIP receptor, alongside GLP-1, is generally considered to add to its effect on appetite and blood sugar control beyond what a GLP-1-only medicine achieves.

Foundayo targets the GLP-1 receptor to regulate appetite by mimicking a natural gut hormone pathway.

Tirzepatide differs from Foundayo because it also acts at GIP, while helping regulate blood sugar by increasing insulin production and slowing stomach emptying. Because that effect is glucose-dependent, low blood sugar is uncommon when tirzepatide is used on its own.

Foundayo's mechanism is more novel in a different way: because it is not a peptide, it binds the GLP-1 receptor at a different site to the body's own GLP-1 and to peptide medicines like tirzepatide, and it activates the receptor's signalling in a more selective way, producing less of one particular downstream signal than a full peptide agonist does.

Researchers are still working out exactly what that selectivity means in practice, and it has been suggested as one reason Foundayo's tolerability profile looks broadly similar to the injectable medicines despite this molecular difference. Our Foundayo oral pill guide goes deeper into this pharmacology.

Where the Names Come From

Part of the confusion is naming itself. Neither product name tells you the mechanism, which is unusual for how medicines are often discussed online.

Neither "orforglipron" nor "tirzepatide" describes what the medicine does in a way a non-specialist would recognise, which is part of why comparison searches lean on the brand names instead, and why the two get typed together even though the underlying medicines work differently. Our Foundayo medicine guide covers the brand-name-versus-active-ingredient distinction for Foundayo specifically in more depth.

Foundayo vs Tirzepatide: How Well Each One Works for Weight Loss

Foundayo and tirzepatide have not been tested against each other in the same trial, so there is no head-to-head figure between these weight loss medications. What exists is separate trial data in broadly similar populations: adults with obesity, or overweight with a weight-related condition, without diabetes, followed for 72 weeks. Reporting the same type of result from each trial's own publication in the New England Journal of Medicine gives a fair, if indirect, comparison from clinical trials.

In separate 72-week trials, the highest studied dose of tirzepatide produced a greater average reduction in body weight than the highest studied dose of Foundayo. However, these results come from different trials with different participants and study designs, so they cannot be treated as a direct head-to-head comparison. The figures can therefore show what each medicine achieved in its own trial, but they cannot predict exactly how one individual would respond to either medicine.

A smaller proportion of people is worth noting too. Weight loss varies between individuals around these averages, so a mean figure describes the group, not any one person's likely result, and treatment choice should be matched to your weight loss goals.

What Happens When You Switch From Tirzepatide to Foundayo?

This is where the two medicines connect directly, rather than just sitting in the same class. A dedicated maintenance trial looked at people who had previously received tirzepatide and whose weight had plateaued. They were then randomised to receive orforglipron or placebo.

People who moved from tirzepatide to Foundayo kept a clearly larger share of the weight they had already lost than those moved to placebo. This does not mean Foundayo matches tirzepatide's own effect on someone still taking it; it means that, for people stepping down from tirzepatide, continuing with a GLP-1 medicine in tablet form preserved more of the result than stopping medicine altogether. Our Foundayo research studies guide covers this trial, named ATTAIN-MAINTAIN, alongside the rest of the Foundayo trial programme.

Foundayo vs Tirzepatide: Taking Them

For some people, Foundayo being a once daily pill also makes it a practical daily pill option if they want to avoid needles, regardless of the efficacy numbers.Unlike oral peptide medicines that require specific administration, Foundayo can be taken once daily without the fasting and water restrictions associated with oral semaglutide.

Starting Dose and Titration

Both medicines are started at a low dose and increased gradually, a process called titration, which is standard practice for this medicine class and is intended to reduce gastrointestinal side effects while the body adjusts.

• Tirzepatide starts at 2.5 mg weekly and is increased in steps, typically at intervals of 4 weeks or more, up to the maintenance dose your prescriber sets
• Foundayo follows the same general principle as a daily tablet, starting low and stepping up over a period of months to its maintenance dose
• Foundayo is gradually increased from its starting dose according to the product information and the patient’s response and tolerability. The maximum dose is 17.2 mg once daily.
• Neither medicine should be started at a high dose, and doses should not be increased faster than directed

Our Foundayo launch and release date guide sets out Foundayo's specific dose ladder in full; the general point here is that the titration principle is shared between the two medicines, even though the schedules themselves differ.

Foundayo vs Tirzepatide: Side Effects

Both medicines share the same broad side effect pattern as other GLP-1 receptor agonists, with common tirzepatide side effects being gastrointestinal issues, including nausea, diarrhoea, vomiting, constipation, and an upset stomach, most common while the dose is being increased. Both medicines have important safety considerations beyond gastrointestinal effects, including pancreatitis, gallbladder problems and kidney injury related to dehydration in some circumstances. Their product information should be checked for the full list of warnings and precautions.

Are Foundayo and Tirzepatide Licensed for the Same Things in the UK?

Broadly, yes. In the UK, both orforglipron and tirzepatide are licensed for weight management and for type 2 diabetes, and tirzepatide is used for type 2 diabetes management, so the two medicines sit alongside each other in the same two indications rather than being licensed for different purposes. Foundayo is approved for weight management and type 2 diabetes. This is worth noting because in some other markets the two medicines' licensed uses have not always lined up in the same way at the same time.

The two medicines are also not interchangeable in your own treatment. Which one, if either, is appropriate is a decision made with a prescriber, based on your own health, other medications and preferences, not something to infer from trial averages alone.

Same Company, Different Medicine: Why Eli Lilly Makes Both

Foundayo and tirzepatide both come from Eli Lilly, and Lilly has been explicit that the two are meant to serve different needs within the same overall approach to weight management, rather than one simply replacing the other. A weekly injectable with the higher average effect sits alongside a daily oral medicine with a more convenient, needle-free routine, so that format and personal circumstances, not just headline efficacy, can shape the choice.

Which Might Suit You?

Neither medicine is universally the better choice. A few honest questions are more useful than a ranking:

• Does a weekly injection put you off starting treatment at all, or does it not bother you?
• Consider whether your weight loss goals prioritise the largest possible average result or the convenience of a tablet.
• Is the higher average weight loss shown with tirzepatide in its own trials important enough to you to outweigh a needle?
• Do you have a preference, or a medical reason, for a longer track record of real-world use over a newer option?
• Have you already been taking tirzepatide and reached a plateau, in which case the switching evidence above may be directly relevant?
• Some weight related health conditions may also influence which option a prescriber discusses.
• Do you have any condition or other medicine that makes one type more suitable, which only a prescriber reviewing your history can properly assess?

These are starting points for a conversation with a prescriber, not a self-selection tool.

When an Online Consultation Makes Sense

If you are weighing up Foundayo, tirzepatide, or whether to switch between GLP-1 medicines, an online consultation with UK-registered prescribers can review your health history, including any personal or family history relevant to thyroid cancer, and discuss which approach may be appropriate for you.

If you experience severe or persistent abdominal pain, repeated vomiting, signs of an allergic reaction, or another symptom that feels urgent while taking a weight-management medicine, seek medical attention promptly rather than waiting for a routine appointment.